News
Essential Pharma acquires Reminyl oral capsules
Essential Pharma has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
Reminyl®, a cholinesterase inhibitor, is an...
Lexeo Therapeutics granted FDA Fast Track designation for Friedreich’s ataxia cardiomyopathy treatment
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, Lexeo Therapeutics’ AAVrh.10hFXN-based gene therapy candidate for the treatment of...
U.S. FDA approves Alvotech and Teva’s SELARSDI, biosimilar to Stelara
The U.S. Food and Drug Administration (FDA) has approved Alvotech and Teva Pharmaceuticals' SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®,...
